Rezdiffra Pregnancy and Lactation Registry
NCT07541469
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- Any age
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Madrigal Pharmaceuticals, Inc.
- Last updated on ClinicalTrials.gov
- April 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Pennsylvania · 1
- Madrigal Pharmaceuticals · West Conshohocken, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.